Jazz’s Midphase Tremor Drug Misses Mark, Future Uncertain
Jazz Pharmaceuticals hits a hurdle as its essential tremor drug trial misses primary endpoint. Awaiting Parkinson's trial results for future ...
- Latest
- Trending
Jazz Pharmaceuticals hits a hurdle as its essential tremor drug trial misses primary endpoint. Awaiting Parkinson's trial results for future ...
Aerovate Therapeutics stock downgraded by BTIG after AV-101 trial setback; mixed analyst views and future pivotal readouts crucial for investors.
Gilead Sciences plans to acquire CymaBay Therapeutics for $4.3 billion, expanding their liver disease portfolio. The deal is expected to ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.